{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:25:49Z","timestamp":1794273949563,"version":"4.9.0"},"reference-count":293,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,2]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Although similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024027904","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:00:16Z","timestamp":1760731216000},"page":"1532-1561","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-8268","authenticated-orcid":false,"given":"C. Michel","family":"Zwaan","sequence":"first","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"2Department of Pediatrics, Erasmus University, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-1662","authenticated-orcid":false,"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"3Division of Oncology and Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"4Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7482-5644","authenticated-orcid":false,"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[{"name":"3Division of Oncology and Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"4Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-4695","authenticated-orcid":false,"given":"Lisa E.","family":"Brodersen","sequence":"additional","affiliation":[{"name":"5Department of Pathology and Laboratory Medicine, Children\u2019s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Buldini","sequence":"additional","affiliation":[{"name":"6Pediatric Hematology, Oncology, and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2449-539X","authenticated-orcid":false,"given":"Barbara","family":"De Moerloose","sequence":"additional","affiliation":[{"name":"7Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8175-1097","authenticated-orcid":false,"given":"Michael N.","family":"Dworzak","sequence":"additional","affiliation":[{"name":"8St Anna Children\u2019s Cancer Research Institute, Vienna, Austria"},{"name":"9Department of Pediatrics and Adolescent Medicine, St Anna Children\u2019s Hospital, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-8519","authenticated-orcid":false,"given":"Linda","family":"Fogelstrand","sequence":"additional","affiliation":[{"name":"10Department of Clinical Chemistry, Region Vastra G\u00f6taland, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"11Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda E. S.","family":"Gibson","sequence":"additional","affiliation":[{"name":"12Haematology Department, Royal Hospital for Children, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-3228","authenticated-orcid":false,"given":"Bianca F.","family":"Goemans","sequence":"additional","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3976-9231","authenticated-orcid":false,"given":"Henrik","family":"Hasle","sequence":"additional","affiliation":[{"name":"13Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy A.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"14Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-8475","authenticated-orcid":false,"given":"Gertjan J. L.","family":"Kaspers","sequence":"additional","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"15Department of Pediatrics, Emma Children\u2019s Hospital, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-0727","authenticated-orcid":false,"given":"Jan-Henning","family":"Klusmann","sequence":"additional","affiliation":[{"name":"16Division of Hematology\/Oncology, Department of Pediatrics, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6659-7036","authenticated-orcid":false,"given":"Matthew A.","family":"Kutny","sequence":"additional","affiliation":[{"name":"17Division of Hematology\/Oncology, Department of Pediatrics, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6022-3439","authenticated-orcid":false,"given":"Thomas","family":"Lehrnbecher","sequence":"additional","affiliation":[{"name":"16Division of Hematology\/Oncology, Department of Pediatrics, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"18Ospedale Pediatrico Bambino Ges\u00f9, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-4423","authenticated-orcid":false,"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"19Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8363-1622","authenticated-orcid":false,"given":"Arnaud","family":"Petit","sequence":"additional","affiliation":[{"name":"20Department of Pediatric Hematology and Oncology, Armand-Trousseau Hospital Assistance Publique\u2013H\u00f4pitaux de Paris and Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4793-5263","authenticated-orcid":false,"given":"Martina","family":"Pigazzi","sequence":"additional","affiliation":[{"name":"6Pediatric Hematology, Oncology, and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-8313","authenticated-orcid":false,"given":"Anne","family":"Tierens","sequence":"additional","affiliation":[{"name":"21Laboratory Medicine Program, University Health Network and University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2854-9014","authenticated-orcid":false,"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[{"name":"22Nemours Center for Cancer and Blood Disorders, AI duPont Hospital for Children, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7027-4483","authenticated-orcid":false,"given":"Dirk","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"23Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-7007","authenticated-orcid":false,"given":"Daisuke","family":"Tomizawa","sequence":"additional","affiliation":[{"name":"24Division of Leukemia and Lymphoma, Children\u2019s Cancer Center, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1203-2371","authenticated-orcid":false,"given":"Todd M.","family":"Cooper","sequence":"additional","affiliation":[{"name":"25Cancer and Blood Disorders Center, Seattle Children\u2019s Hospital, Seattle, WA"},{"name":"26Department of Pediatrics, University of Washington School of Medicine, Seatlle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2026040211214354200_bib1","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2026040211214354200_bib2","first-page":"2813","article-title":"How I treat AML incorporating the updated classifications and guidelines","volume":"141","author":"El Chaer","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026040211214354200_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026040211214354200_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026040211214354200_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/2159-8290.CD-21-1094","article-title":"A summary of the inaugural WHO Classification of Pediatric Tumors: transitioning from the optical into the molecular era","volume":"12","author":"Pfister","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"2026040211214354200_bib6","doi-asserted-by":"crossref","first-page":"100397","DOI":"10.1016\/j.modpat.2023.100397","article-title":"Fifth edition of the World Health classification of tumors of the hematopoietic and lymphoid tissue: myeloid neoplasms","volume":"37","author":"Loghavi","year":"2024","journal-title":"Mod Pathol"},{"issue":"7","key":"2026040211214354200_bib7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2026040211214354200_bib8","doi-asserted-by":"crossref","first-page":"e26664","DOI":"10.1002\/pbc.26664","article-title":"Characteristics and outcome in patients with central nervous system involvement treated in European Pediatric Acute Myeloid Leukemia study groups","volume":"64","author":"Creutzig","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2026040211214354200_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"issue":"4","key":"2026040211214354200_bib10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000496097","article-title":"Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia","volume":"141","author":"Bain","year":"2019","journal-title":"Acta Haematol"},{"issue":"1","key":"2026040211214354200_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cyto.b.21518","article-title":"AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia","volume":"94","author":"Dworzak","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"2026040211214354200_bib12","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3390\/cancers14061583","article-title":"Immunophenotypic analysis of acute megakaryoblastic leukemia: a EuroFlow Study","volume":"14","author":"Brouwer","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"2026040211214354200_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"de Rooij","year":"2017","journal-title":"Nat Genet"},{"issue":"6","key":"2026040211214354200_bib14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/cyto.b.21082","article-title":"Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome","volume":"84","author":"Boztug","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"7","key":"2026040211214354200_bib15","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/sj.leu.2402504","article-title":"Antigen expression patterns reflecting genotype of acute leukemias","volume":"16","author":"Hrus\u00e1k","year":"2002","journal-title":"Leukemia"},{"issue":"10","key":"2026040211214354200_bib16","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/leu.2016.119","article-title":"A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group","volume":"30","author":"Eidenschink Brodersen","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"2026040211214354200_bib17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/cyto.a.24339","article-title":"CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript","volume":"99","author":"Zangrando","year":"2021","journal-title":"Cytometry A"},{"issue":"5","key":"2026040211214354200_bib18","first-page":"405","article-title":"The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements","volume":"84","author":"Orfao","year":"1999","journal-title":"Haematologica"},{"issue":"3","key":"2026040211214354200_bib19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood.V87.3.1123.bloodjournal8731123","article-title":"The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23","volume":"87","author":"Smith","year":"1996","journal-title":"Blood"},{"issue":"9","key":"2026040211214354200_bib20","first-page":"2275","article-title":"Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023","volume":"108","author":"Egan","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"2026040211214354200_bib21","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3324\/haematol.2023.283817","article-title":"Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?","volume":"109","author":"Naik","year":"2024","journal-title":"Haematologica"},{"key":"2026040211214354200_bib22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fped.2019.00412","article-title":"Flow-cytometric monitoring of minimal residual disease in pediatric patients with acute myeloid leukemia: recent advances and future strategies","volume":"7","author":"Buldini","year":"2019","journal-title":"Front Pediatr"},{"key":"2026040211214354200_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/9781118795569","volume-title":"Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells","author":"Sverre Heim","year":"2015","edition":"4th ed"},{"issue":"8","key":"2026040211214354200_bib24","first-page":"1861","article-title":"Integrated genomic analysis to reduce chromosomal analysis for the diagnosis of pediatric hematologic malignancies: addressing the shortage of cytogenetic technologists","volume":"110","author":"Li","year":"2025","journal-title":"Haematologica"},{"key":"2026040211214354200_bib25","volume-title":"An International System for Human Cytogenomic Nomenclature (2020)","year":"2020"},{"issue":"1","key":"2026040211214354200_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"2026040211214354200_bib27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","article-title":"A new genomic framework to categorize pediatric acute myeloid leukemia","volume":"56","author":"Umeda","year":"2024","journal-title":"Nat Genet"},{"issue":"13","key":"2026040211214354200_bib28","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.2020009652","article-title":"CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group","volume":"138","author":"Tarlock","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026040211214354200_bib29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/gcc.23147","article-title":"TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia","volume":"62","author":"Hara","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2026040211214354200_bib30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2643-3230.BCD-21-0160","article-title":"Integrated genomic analysis identifies UBTF tandem duplications as a recurrent lesion in pediatric acute myeloid leukemia","volume":"3","author":"Umeda","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026040211214354200_bib31","first-page":"1609128","article-title":"Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia","volume":"2019","author":"Niktoreh","year":"2019","journal-title":"J Oncol"},{"issue":"6","key":"2026040211214354200_bib32","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjh.13366","article-title":"The applicability of the WHO classification in paediatric AML. A NOPHO-AML study","volume":"169","author":"Sandahl","year":"2015","journal-title":"Br J Haematol"},{"issue":"22","key":"2026040211214354200_bib33","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1182\/blood-2011-05-353185","article-title":"Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia","volume":"118","author":"Staffas","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2026040211214354200_bib34","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/pbc.24168","article-title":"Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML","volume":"59","author":"Rochowski","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2026040211214354200_bib35","first-page":"2459","article-title":"UBTF tandem duplications in pediatric myelodysplastic syndrome and acute myeloid leukemia: implications for clinical screening and diagnosis","volume":"109","author":"Barajas","year":"2024","journal-title":"Haematologica"},{"key":"2026040211214354200_bib36","unstructured":"Atlas of Genetics and Cytogenetics in Oncology and Haematology. 2024. https:\/\/atlasgeneticsoncology.org."},{"issue":"1","key":"2026040211214354200_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ejhg.2015.35","article-title":"Guidelines for cytogenetic investigations in tumours","volume":"24","author":"Hastings","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"2026040211214354200_bib38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N Engl J Med"},{"issue":"28","key":"2026040211214354200_bib39","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III Children's Oncology Group Trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026040211214354200_bib40","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.22.02120","article-title":"Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-M\u00fcnster Study Group","volume":"41","author":"van Weelderen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026040211214354200_bib41","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/bloodadvances.2023011771","article-title":"Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia","volume":"8","author":"van Weelderen","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2026040211214354200_bib42","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjh.15587","article-title":"Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A NOPHO-DBH-AML study","volume":"183","author":"Bager","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"2026040211214354200_bib43","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3390\/cancers14092058","article-title":"Optical genome mapping as a diagnostic tool in pediatric acute myeloid leukemia","volume":"14","author":"Suttorp","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026040211214354200_bib44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cancergen.2019.08.005","article-title":"Rapid detection of chromosomal translocation and precise breakpoint characterization in acute myeloid leukemia by nanopore long-read sequencing","volume":"239","author":"Au","year":"2019","journal-title":"Cancer Genet"},{"issue":"17","key":"2026040211214354200_bib45","first-page":"2156","article-title":"CREBBP alterations are associated with a poor prognosis in de novo AML","volume":"141","author":"Lamble","year":"2023","journal-title":"Blood"},{"issue":"15","key":"2026040211214354200_bib46","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2013-02-485524","article-title":"Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-M\u00fcnster AML-study group","volume":"122","author":"Coenen","year":"2013","journal-title":"Blood"},{"key":"2026040211214354200_bib47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fped.2017.00248","article-title":"Targeting FLT3 signaling in childhood acute myeloid leukemia","volume":"5","author":"Sexauer","year":"2017","journal-title":"Front Pediatr"},{"issue":"1","key":"2026040211214354200_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V97.1.89","article-title":"Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia","volume":"97","author":"Meshinchi","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2026040211214354200_bib49","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood-2002-12-3627","article-title":"FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance","volume":"102","author":"Zwaan","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2026040211214354200_bib50","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood-2006-03-009233","article-title":"Clinical implications of FLT3 mutations in pediatric AML","volume":"108","author":"Meshinchi","year":"2006","journal-title":"Blood"},{"issue":"18","key":"2026040211214354200_bib51","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ acute myeloid leukemia: a report from the Children's Oncology Group Protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026040211214354200_bib52","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/bloodadvances.2023011980","article-title":"Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia","volume":"8","author":"Tarlock","year":"2024","journal-title":"Blood Adv"},{"issue":"23","key":"2026040211214354200_bib53","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1182\/blood-2008-09-177949","article-title":"Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia","volume":"113","author":"Hollink","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2026040211214354200_bib54","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3324\/haematol.2010.038976","article-title":"Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia","volume":"96","author":"Balgobind","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2026040211214354200_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3324\/haematol.2021.280250","article-title":"Analysis of rare driving events in pediatric acute myeloid leukemia","volume":"108","author":"Noort","year":"2023","journal-title":"Haematologica"},{"issue":"8","key":"2026040211214354200_bib56","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO-24-01715","article-title":"Influence of nucleophosmin (NPM1) genotypes on outcome of patients with AML: an AIEOP-BFM and COG-SWOG Intergroup Collaboration","volume":"43","author":"Tregnago","year":"2025","journal-title":"J Clin Oncol"},{"issue":"26","key":"2026040211214354200_bib57","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1182\/blood-2008-10-184747","article-title":"Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group","volume":"113","author":"Ho","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2026040211214354200_bib58","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.2019004179","article-title":"Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia","volume":"135","author":"Tarlock","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2026040211214354200_bib59","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1038\/leu.2011.142","article-title":"Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups","volume":"25","author":"Damm","year":"2011","journal-title":"Leukemia"},{"issue":"19","key":"2026040211214354200_bib60","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis","volume":"7","author":"Zarnegar-Lumley","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026040211214354200_bib61","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/pbc.23179","article-title":"Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group","volume":"57","author":"Ho","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2026040211214354200_bib62","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/leu.2011.210","article-title":"Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model","volume":"26","author":"Hollink","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2026040211214354200_bib63","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.16229","article-title":"TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia","volume":"188","author":"Cucchi","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2026040211214354200_bib64","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s42003-023-04732-2","article-title":"Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia","volume":"6","author":"Cheng","year":"2023","journal-title":"Commun Biol"},{"issue":"25","key":"2026040211214354200_bib65","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood.2023022247","article-title":"Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms","volume":"143","author":"Sato","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026040211214354200_bib66","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood-2024-208864","article-title":"Comprehensive characterization of rare recurrent mutations in pediatric AML [abstract]","volume":"144","author":"Lamble","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026040211214354200_bib67","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood-2021-147565","article-title":"KMT2A partial tandem duplications (KMT2A-PTD) is a rare, but recurrent genomic event in childhood AML and associated with high rate of co-occurring FLT3 mutations [abstract]","volume":"138","author":"Kirkey","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026040211214354200_bib68","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood-2010-02-268953","article-title":"Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group","volume":"116","author":"Ho","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2026040211214354200_bib69","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3324\/haematol.2020.269431","article-title":"Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia","volume":"107","author":"Kaburagi","year":"2022","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026040211214354200_bib70","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1182\/blood-2022-170747","article-title":"RAS pathway alterations in pediatric AML patients [abstract]","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026040211214354200_bib71","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2024-202833","article-title":"Contrasting clinical implications of NRAS vs. KRAS mutations in AML - only KRAS mutations are associated with adverse outcome [abstract]","volume":"144","author":"Colgan","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026040211214354200_bib72","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/leu.2010.47","article-title":"EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia","volume":"24","author":"Balgobind","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2026040211214354200_bib73","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2010.30.6829","article-title":"Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate","volume":"29","author":"Abrahamsson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026040211214354200_bib74","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia","volume":"8","author":"Cheson","year":"1990","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026040211214354200_bib75","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026040211214354200_bib76","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2026040211214354200_bib77","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2026040211214354200_bib78","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.2009.25.1066","article-title":"Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study","volume":"28","author":"Walter","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026040211214354200_bib79","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41375-024-02143-8","article-title":"Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts","volume":"38","author":"Appelbaum","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2026040211214354200_bib80","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/cancers14030616","article-title":"Blood count recovery following induction therapy for acute myeloid leukemia in children does not predict survival","volume":"14","author":"Pommert","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"2026040211214354200_bib81","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2023-185647","article-title":"Establishing real-world data-driven response criteria in pediatric acute myeloid leukemia [abstract]","volume":"142","author":"Aplenc","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2026040211214354200_bib82","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1002\/cncr.30791","article-title":"Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials","volume":"123","author":"Alexander","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"2026040211214354200_bib83","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026040211214354200_bib84","doi-asserted-by":"crossref","first-page":"103272","DOI":"10.1016\/j.eclinm.2025.103272","article-title":"No evidence of leukaemia (NEL) as a response criteria in paediatric AML: a multicentre analysis","volume":"84","author":"Antoniou","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"23 suppl","key":"2026040211214354200_bib85","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/JCO.2024.42.23_suppl.169","article-title":"Collaborative data sharing: the International Acute Myeloid Leukemia Consortium (INTERACT)","volume":"42","author":"Tomizawa","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026040211214354200_bib86","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2026040211214354200_bib87","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/bloodadvances.2020002070","article-title":"Morphologic remission status is limited compared to DeltaN flow cytometry: a Children's Oncology Group AAML0531 report","volume":"4","author":"Brodersen","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2026040211214354200_bib88","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2010.153","article-title":"Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97\/MRC AML12 protocol","volume":"24","author":"van der Velden","year":"2010","journal-title":"Leukemia"},{"issue":"29","key":"2026040211214354200_bib89","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1200\/JCO.2011.41.5323","article-title":"Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia","volume":"30","author":"Inaba","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026040211214354200_bib90","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14093","article-title":"Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study","volume":"174","author":"Tierens","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2026040211214354200_bib91","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.14523","article-title":"Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol","volume":"177","author":"Buldini","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"2026040211214354200_bib92","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12885-023-11784-4","article-title":"Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia","volume":"24","author":"Zheng","year":"2024","journal-title":"BMC Cancer"},{"issue":"22","key":"2026040211214354200_bib93","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.05.4312","article-title":"Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group","volume":"24","author":"MRD-AML-BFM Study Group","year":"2006","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026040211214354200_bib94","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1182\/bloodadvances.2022009534","article-title":"Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia","volume":"7","author":"Karol","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2026040211214354200_bib95","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"18","key":"2026040211214354200_bib96","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1200\/JCO.23.01841","article-title":"Mitoxantrone versus liposomal daunorubicin in induction of pediatric AML with risk stratification based on flow cytometry measurement of residual disease","volume":"42","author":"Tierens","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026040211214354200_bib97","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2141.2003.04610.x","article-title":"Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia","volume":"123","author":"Coustan-Smith","year":"2003","journal-title":"Br J Haematol"},{"issue":"12","key":"2026040211214354200_bib98","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2026040211214354200_bib99","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.3390\/cancers13112597","article-title":"AML\/normal progenitor balance instead of total tumor load (MRD) accounts for prognostic impact of flowcytometric residual disease in AML","volume":"13","author":"Hanekamp","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"26","key":"2026040211214354200_bib100","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026040211214354200_bib101","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/ijlh.13935","article-title":"Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukaemia","volume":"44","author":"Karlsson","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"2026040211214354200_bib102","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3324\/haematol.2022.282424","article-title":"Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia","volume":"109","author":"Maurer-Granofszky","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"2026040211214354200_bib103","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.3324\/haematol.2014.114579","article-title":"Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement","volume":"100","author":"Pigazzi","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2026040211214354200_bib104","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/leu.2016.177","article-title":"Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group","volume":"31","author":"Manara","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2026040211214354200_bib105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ped.13440","article-title":"Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia","volume":"60","author":"Matsuo","year":"2018","journal-title":"Pediatr Int"},{"issue":"1","key":"2026040211214354200_bib106","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2404015","article-title":"Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]","volume":"20","author":"Perea","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"2026040211214354200_bib107","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/biomedicines10071530","article-title":"Molecular measurable residual disease assessment before hematopoietic stem cell transplantation in pediatric acute myeloid leukemia patients: a retrospective study by the I-BFM Study Group","volume":"10","author":"Benetton","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"2026040211214354200_bib108","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bjh.16560","article-title":"Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia","volume":"190","author":"Juul-Dam","year":"2020","journal-title":"Br J Haematol"},{"issue":"12","key":"2026040211214354200_bib109","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"issue":"12","key":"2026040211214354200_bib110","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"2026040211214354200_bib111","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.leu.2404082","article-title":"Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations","volume":"20","author":"Burmeister","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"2026040211214354200_bib112","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jmoldx.2018.08.004","article-title":"Accurate and sensitive analysis of minimal residual disease in acute myeloid leukemia using deep sequencing of single nucleotide variations","volume":"21","author":"Delsing Malmberg","year":"2019","journal-title":"J Mol Diagn"},{"issue":"4","key":"2026040211214354200_bib113","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijlh.13608","article-title":"Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia","volume":"43","author":"Pettersson","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"12","key":"2026040211214354200_bib114","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jmoldx.2021.09.004","article-title":"Measurable residual disease monitoring of SPAG6, ST18, PRAME, and XAGE1A expression in peripheral blood may detect imminent relapse in childhood acute myeloid leukemia","volume":"23","author":"Skou","year":"2021","journal-title":"J Mol Diagn"},{"issue":"1","key":"2026040211214354200_bib115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41375-023-02083-9","article-title":"Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study","volume":"38","author":"Zaliova","year":"2024","journal-title":"Leukemia"},{"issue":"12","key":"2026040211214354200_bib116","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2026040211214354200_bib117","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","article-title":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease","volume":"36","author":"Zuna","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026040211214354200_bib118","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2024-205666","article-title":"A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin (GO) to CPX-351 with GO - a report from the Children\u2019s Oncology Group [abstract]","volume":"144","author":"Pollard","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026040211214354200_bib119","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood-2023-187251","article-title":"A randomized comparison of liposomal daunorubicin\/daunorubicin combined with low-dose cytarabine and etoposide or high-dose cytarabine and fludarabine in induction treatment of pediatric AML using MRD-based risk stratification in the NOPHO-DBH AML 2012 Protocol [abstract]","volume":"142","author":"De Moerloose","year":"2023","journal-title":"Blood"},{"issue":"27","key":"2026040211214354200_bib120","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative efforts driving progress in pediatric acute myeloid leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026040211214354200_bib121","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021011694","article-title":"How I treat pediatric acute myeloid leukemia","volume":"138","author":"Rubnitz","year":"2021","journal-title":"Blood"},{"issue":"suppl 6","key":"2026040211214354200_bib122","doi-asserted-by":"crossref","first-page":"e30584","DOI":"10.1002\/pbc.30584","article-title":"Children's Oncology Group's 2023 blueprint for research: myeloid neoplasms","volume":"70 suppl 6","author":"Cooper","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"2026040211214354200_bib123","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.3390\/cancers15164171","article-title":"Risk-stratified therapy for pediatric acute myeloid leukemia","volume":"15","author":"Tomizawa","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2026040211214354200_bib124","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/cncr.34751","article-title":"Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods","volume":"129","author":"Christakopoulos","year":"2023","journal-title":"Cancer"},{"issue":"9","key":"2026040211214354200_bib125","first-page":"2873","article-title":"Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 protocol","volume":"109","author":"Zeller","year":"2024","journal-title":"Haematologica"},{"issue":"23","key":"2026040211214354200_bib126","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1200\/JCO.19.00327","article-title":"Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: the AML08 multicenter, randomized phase III trial","volume":"37","author":"Rubnitz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026040211214354200_bib127","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2019-130969","article-title":"Impact of a risk-adapted treatment approach in pediatric AML: a report of the AML-BFM Registry 2012 [abstract]","volume":"134","author":"Rasche","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026040211214354200_bib128","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41375-023-02075-9","article-title":"High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia","volume":"38","author":"Tomizawa","year":"2024","journal-title":"Leukemia"},{"issue":"31","key":"2026040211214354200_bib129","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.22.02836","article-title":"Homoharringtonine-based induction regimen improved the remission rate and survival rate in chinese childhood AML: a report from the CCLG-AML 2015 Protocol study","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026040211214354200_bib130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood-2023-188682","article-title":"Final results of the AIEOP (Associazione Italiana Ematologia\/Oncologia Pediatrica) AML 2013 prospective randomized trial in childhood acute myeloid leukemia (AML) [abstract]","volume":"142","author":"Locatelli","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026040211214354200_bib131","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/blood-2024-198419","article-title":"Favourable outcomes in newly diagnosed paediatric AML with gemtuzumab ozogamicin and risk-stratified therapy: results from the international phase III Myechild 01 trial [abstract]","volume":"144","author":"Gibson","year":"2024","journal-title":"Blood"},{"issue":"25","key":"2026040211214354200_bib132","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","article-title":"Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial","volume":"129","author":"Uffmann","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2026040211214354200_bib133","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41375-021-01157-w","article-title":"Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome","volume":"35","author":"Taga","year":"2021","journal-title":"Leukemia"},{"issue":"23","key":"2026040211214354200_bib134","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2021012206","article-title":"High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial","volume":"138","author":"Hitzler","year":"2021","journal-title":"Blood"},{"issue":"25","key":"2026040211214354200_bib135","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2017-01-764324","article-title":"Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial","volume":"129","author":"Taub","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026040211214354200_bib136","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2018-03-836528","article-title":"Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL","volume":"132","author":"Testi","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026040211214354200_bib137","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41408-023-00949-w","article-title":"Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group","volume":"13","author":"Huang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026040211214354200_bib138","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","article-title":"Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group AAML1331 trial","volume":"8","author":"Kutny","year":"2022","journal-title":"JAMA Oncol"},{"issue":"28","key":"2026040211214354200_bib139","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1200\/JCO.20.03096","article-title":"Arsenic combined with all-trans retinoic acid for pediatric acute promyelocytic leukemia: report from the CCLG-APL2016 Protocol study","volume":"39","author":"Zheng","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026040211214354200_bib140","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2008.18.7948","article-title":"Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group","volume":"27","author":"Tsukimoto","year":"2009","journal-title":"J Clin Oncol"},{"issue":"27","key":"2026040211214354200_bib141","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"27","key":"2026040211214354200_bib142","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026040211214354200_bib143","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1200\/JCO.19.03306","article-title":"Phase I\/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: a report from the Children's Oncology Group","volume":"38","author":"Cooper","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026040211214354200_bib144","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026040211214354200_bib145","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","article-title":"CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children's Oncology Group Trial AAML0531","volume":"34","author":"Pollard","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026040211214354200_bib146","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08851.x","article-title":"Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial","volume":"155","author":"Gibson","year":"2011","journal-title":"Br J Haematol"},{"issue":"12","key":"2026040211214354200_bib147","doi-asserted-by":"crossref","first-page":"e29281","DOI":"10.1002\/pbc.29281","article-title":"Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: a report from the Children's Oncology Group","volume":"68","author":"Elgarten","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2026040211214354200_bib148","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2026040211214354200_bib149","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/pbc.22511","article-title":"The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study","volume":"55","author":"Johnston","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026040211214354200_bib150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MPH.0000000000001034","article-title":"Acute myeloid leukemia with central nervous system involvement in children: experience from the French Protocol Analysis ELAM02","volume":"40","author":"Felix","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"issue":"9","key":"2026040211214354200_bib151","first-page":"530","article-title":"Hematopoietic cell transplantation in the treatment of pediatric acute myelogenous leukemia and myelodysplastic syndromes: guidelines from the American Society of Transplantation and Cellular Therapy","volume":"28","author":"Tarlock","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"2026040211214354200_bib152","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/bmt.2017.147","article-title":"Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group","volume":"52","author":"Balduzzi","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"2026040211214354200_bib153","doi-asserted-by":"crossref","first-page":"e30407","DOI":"10.1002\/pbc.30407","article-title":"Fertility preservation in pediatric leukemia and lymphoma: a report from the Children's Oncology Group","volume":"70","author":"Close","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2026040211214354200_bib154","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.3324\/haematol.2018.211094","article-title":"Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies","volume":"104","author":"Poirot","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"2026040211214354200_bib155","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/bloodadvances.2021005492","article-title":"Unrelated donor \u03b1\/\u03b2 T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia","volume":"6","author":"Leahy","year":"2022","journal-title":"Blood Adv"},{"issue":"18","key":"2026040211214354200_bib156","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1182\/bloodadvances.2023010281","article-title":"Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias","volume":"7","author":"Fierro-Pineda","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2026040211214354200_bib157","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbmt.2016.11.022","article-title":"Impact of conditioning regimen on outcomes for children with acute myeloid leukemia undergoing transplantation in first complete remission. an analysis on behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation","volume":"23","author":"Lucchini","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2026040211214354200_bib158","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41409-020-01201-w","article-title":"Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens","volume":"56","author":"Versluys","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2026040211214354200_bib159","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00277-022-04965-x","article-title":"Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis","volume":"101","author":"Masetti","year":"2022","journal-title":"Ann Hematol"},{"issue":"12","key":"2026040211214354200_bib160","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.bbmt.2015.08.011","article-title":"Comparison of outcomes for pediatric patients with acute myeloid leukemia in remission and undergoing allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens based on either intravenous busulfan or total body irradiation: a report from the Japanese Society for Hematopoietic Cell Transplantation","volume":"21","author":"Ishida","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2026040211214354200_bib161","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-02-409813","article-title":"Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2026040211214354200_bib162","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol"},{"issue":"6","key":"2026040211214354200_bib163","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/pbc.25437","article-title":"Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3\/ITD acute myeloid leukemia","volume":"62","author":"Tarlock","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2026040211214354200_bib164","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ajh.24959","article-title":"Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant","volume":"93","author":"Sandmaier","year":"2018","journal-title":"Am J Hematol"},{"issue":"26","key":"2026040211214354200_bib165","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026040211214354200_bib166","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026040211214354200_bib167","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1542\/peds.2008-3688","article-title":"Long-term follow-up care for pediatric cancer survivors","volume":"123","author":"American Academy of Pediatrics Section on Hematology\/Oncology Children's Oncology Group","year":"2009","journal-title":"Pediatrics"},{"issue":"18","key":"2026040211214354200_bib168","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood.2023019804","article-title":"How I treat long-term survivors of childhood acute leukemia","volume":"143","author":"Saultier","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026040211214354200_bib169","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.17449","article-title":"Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse","volume":"195","author":"Skou","year":"2021","journal-title":"Br J Haematol"},{"issue":"16","key":"2026040211214354200_bib170","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/cncr.28674","article-title":"AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia","volume":"120","author":"Cooper","year":"2014","journal-title":"Cancer"},{"issue":"10","key":"2026040211214354200_bib171","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/pbc.25117","article-title":"A phase 2 study of bortezomib combined with either idarubicin\/cytarabine or cytarabine\/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group","volume":"61","author":"Horton","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026040211214354200_bib172","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/bjh.18844","article-title":"Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population","volume":"202","author":"Doan","year":"2023","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2026040211214354200_bib173","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood-2022-168818","article-title":"ITCC-101\/APAL2020D: a randomized phase 3 trial of fludarabine\/cytarabine\/gemtuzumab ozogamycin with or without venetoclax in children with relapsed acute myeloid leukemia [abstract]","volume":"140","author":"Ishimaru","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026040211214354200_bib174","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ajh.26510","article-title":"Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed\/refractory AML: report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium","volume":"97","author":"Pommert","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"2026040211214354200_bib175","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1158\/1078-0432.CCR-19-1251","article-title":"Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: a TACL pilot study","volume":"26","author":"Burke","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026040211214354200_bib176","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/cancers16030496","article-title":"Nivolumab plus 5-azacitidine in pediatric relapsed\/refractory acute myeloid leukemia (AML): phase I\/II trial results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium","volume":"16","author":"Verma","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"22","key":"2026040211214354200_bib177","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.2024026598","article-title":"Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements","volume":"145","author":"Egan","year":"2025","journal-title":"Blood"},{"issue":"7954","key":"2026040211214354200_bib178","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"1","key":"2026040211214354200_bib179","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026040211214354200_bib180","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"2026040211214354200_bib181","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2020.04.038","article-title":"Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"136","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"2026040211214354200_bib182","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/cancers16010078","article-title":"The PedAL\/EuPAL project: a global initiative to address the unmet medical needs of pediatric patients with relapsed or refractory acute myeloid leukemia","volume":"16","author":"Ceolin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2026040211214354200_bib183","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2026040211214354200_bib184","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41408-021-00561-w","article-title":"Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants","volume":"11","author":"Cicconi","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026040211214354200_bib185","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/blood-2004-05-1971","article-title":"GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children","volume":"106","author":"Testi","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2026040211214354200_bib186","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-017-3042-6","article-title":"Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy","volume":"96","author":"Abla","year":"2017","journal-title":"Ann Hematol"},{"issue":"1","key":"2026040211214354200_bib187","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/pbc.24585","article-title":"Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009","volume":"61","author":"Fisher","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2026040211214354200_bib188","first-page":"11","article-title":"Advances in pediatric acute promyelocytic leukemia","volume":"7","author":"Conneely","year":"2020","journal-title":"Children (Basel)"},{"issue":"2","key":"2026040211214354200_bib189","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2026040211214354200_bib190","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.leukres.2007.06.005","article-title":"Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment","volume":"32","author":"Au","year":"2008","journal-title":"Leuk Res"},{"issue":"suppl 2","key":"2026040211214354200_bib191","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0049-3848(10)70013-X","article-title":"Open issues on bleeding and thrombosis in acute promyelocytic leukemia","volume":"125","author":"Sanz","year":"2010","journal-title":"Thromb Res"},{"issue":"7","key":"2026040211214354200_bib192","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2017-09-806489","article-title":"A landscape of germ line mutations in a cohort of inherited bone marrow failure patients","volume":"131","author":"Bluteau","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2026040211214354200_bib193","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1038\/s41375-022-01731-w","article-title":"Classification of rare pediatric myeloid neoplasia-Quo vadis?","volume":"36","author":"Niemeyer","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2026040211214354200_bib194","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00428-022-03447-9","article-title":"The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia","volume":"482","author":"Rudelius","year":"2023","journal-title":"Virchows Arch"},{"issue":"8","key":"2026040211214354200_bib195","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/s41375-021-01137-0","article-title":"Germline variants drive myelodysplastic syndrome in young adults","volume":"35","author":"Feurstein","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2026040211214354200_bib196","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41375-023-01955-4","article-title":"Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis","volume":"37","author":"Reinig","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"2026040211214354200_bib197","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.2023021165","article-title":"Germ line risk variants: beyond cancer","volume":"142","author":"Godley","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026040211214354200_bib198","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/leu.2016.342","article-title":"Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants","volume":"31","author":"Pastor","year":"2017","journal-title":"Leukemia"},{"issue":"23","key":"2026040211214354200_bib199","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa041331","article-title":"Mutation of CEBPA in familial acute myeloid leukemia","volume":"351","author":"Smith","year":"2004","journal-title":"N Engl J Med"},{"issue":"21","key":"2026040211214354200_bib200","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood.2019003357","article-title":"High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML","volume":"135","author":"Simon","year":"2020","journal-title":"Blood"},{"issue":"13","key":"2026040211214354200_bib201","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2022017739","article-title":"Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances","volume":"141","author":"Reilly","year":"2023","journal-title":"Blood"},{"issue":"23","key":"2026040211214354200_bib202","first-page":"2853","article-title":"The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia","volume":"141","author":"Hakkarainen","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026040211214354200_bib203","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","article-title":"Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents","volume":"127","author":"Wlodarski","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2026040211214354200_bib204","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41591-021-01511-6","article-title":"Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9\/SAMD9L syndromes","volume":"27","author":"Sahoo","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"2026040211214354200_bib205","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ng.3569","article-title":"SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7","volume":"48","author":"Narumi","year":"2016","journal-title":"Nat Genet"},{"issue":"8","key":"2026040211214354200_bib206","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1007\/s10875-023-01583-8","article-title":"A nationwide study of GATA2 deficiency in Italy reveals novel symptoms and genotype-phenotype association","volume":"43","author":"Roncareggi","year":"2023","journal-title":"J Clin Immunol"},{"issue":"13","key":"2026040211214354200_bib207","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood-2017-09-765214","article-title":"How I treat myelodysplastic syndromes of childhood","volume":"131","author":"Locatelli","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2026040211214354200_bib208","doi-asserted-by":"crossref","first-page":"e994","DOI":"10.1016\/S2352-3026(23)00265-X","article-title":"Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Gurnari","year":"2023","journal-title":"Lancet Haematol"},{"issue":"11","key":"2026040211214354200_bib209","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3324\/haematol.2021.279332","article-title":"A novel classification of hematologic conditions in patients with Fanconi anemia","volume":"106","author":"Behrens","year":"2021","journal-title":"Haematologica"},{"issue":"18","key":"2026040211214354200_bib210","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1182\/blood-2016-08-732610","article-title":"Acute myeloid leukemia with TP53 germ line mutations","volume":"128","author":"Zebisch","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2026040211214354200_bib211","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S1470-2045(21)00425-3","article-title":"Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"22","author":"Thariat","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"2026040211214354200_bib212","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1038\/s41375-019-0520-y","article-title":"Risk of therapy-related myelodysplastic syndrome\/acute myeloid leukemia after childhood cancer: a population-based study","volume":"33","author":"Advani","year":"2019","journal-title":"Leukemia"},{"issue":"23","key":"2026040211214354200_bib213","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2011-02-335158","article-title":"Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"117","author":"Nottage","year":"2011","journal-title":"Blood"},{"issue":"suppl 1","key":"2026040211214354200_bib214","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1182\/blood-2019-131911","article-title":"Treatment-related acute myeloid leukemia in children [abstract]","volume":"134","author":"Waack","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026040211214354200_bib215","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41467-021-21255-8","article-title":"The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms","volume":"12","author":"Schwartz","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"2026040211214354200_bib216","first-page":"1860","article-title":"Elevated mutational age in blood of children treated for cancer contributes to therapy-related myeloid neoplasms","volume":"12","author":"Bertrums","year":"2022","journal-title":"Cancer Discov"},{"issue":"12","key":"2026040211214354200_bib217","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/s41409-021-01448-x","article-title":"Outcomes of pediatric patients with therapy-related myeloid neoplasms","volume":"56","author":"Sharma","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2026040211214354200_bib218","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood.2024024011","article-title":"How I treat: secondary acute myeloid leukemia","volume":"145","author":"Green","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026040211214354200_bib219","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/s41467-024-50384-z","article-title":"Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms","volume":"15","author":"Bertrums","year":"2024","journal-title":"Nat Commun"},{"issue":"9199","key":"2026040211214354200_bib220","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down's syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"2026040211214354200_bib221","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat Genet"},{"issue":"6","key":"2026040211214354200_bib222","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-10-118810","article-title":"Treatment and prognostic impact of transient leukemia in neonates with Down syndrome","volume":"111","author":"Klusmann","year":"2008","journal-title":"Blood"},{"issue":"26","key":"2026040211214354200_bib223","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","article-title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971","volume":"118","author":"Gamis","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2026040211214354200_bib224","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2013-07-515148","article-title":"GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2026040211214354200_bib225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/a-1532-2016","article-title":"Recommendations for diagnosis and treatment of children with transient abnormal myelopoiesis (TAM) and myeloid leukemia in Down syndrome (ML-DS)","volume":"233","author":"Al-Kershi","year":"2021","journal-title":"Klin Padiatr"},{"issue":"5","key":"2026040211214354200_bib226","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41375-021-01171-y","article-title":"Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome","volume":"35","author":"Yamato","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"2026040211214354200_bib227","doi-asserted-by":"crossref","first-page":"e2022057010","DOI":"10.1542\/peds.2022-057010","article-title":"Health supervision for children and adolescents with Down syndrome","volume":"149","author":"Bull","year":"2022","journal-title":"Pediatrics"},{"issue":"2","key":"2026040211214354200_bib228","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bjh.15390","article-title":"Guidelines for the investigation and management of transient leukaemia of Down syndrome","volume":"182","author":"Tunstall","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"2026040211214354200_bib229","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-2005-836510","article-title":"Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts","volume":"217","author":"Langebrake","year":"2005","journal-title":"Klin Padiatr"},{"issue":"13","key":"2026040211214354200_bib230","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/bloodadvances.2018018945","article-title":"Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study","volume":"2","author":"Flasinski","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"2026040211214354200_bib231","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1002\/cncr.27484","article-title":"Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group","volume":"118","author":"Sorrell","year":"2012","journal-title":"Cancer"},{"issue":"7","key":"2026040211214354200_bib232","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/sj.leu.2405060","article-title":"Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML","volume":"22","author":"Hasle","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2026040211214354200_bib233","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2019.08.014","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell"},{"issue":"16","key":"2026040211214354200_bib234","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.3390\/cancers13164144","article-title":"The mutational landscape of myeloid leukaemia in Down syndrome","volume":"13","author":"de Castro","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026040211214354200_bib235","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.V99.1.245","article-title":"Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome","volume":"99","author":"Zwaan","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2026040211214354200_bib236","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/sj.leu.2403814","article-title":"AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity","volume":"19","author":"Creutzig","year":"2005","journal-title":"Leukemia"},{"issue":"5","key":"2026040211214354200_bib237","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00277-005-0045-5","article-title":"Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature","volume":"85","author":"Abildgaard","year":"2006","journal-title":"Ann Hematol"},{"issue":"5","key":"2026040211214354200_bib238","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2141.2005.05906.x","article-title":"Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials","volume":"132","author":"Rao","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"2026040211214354200_bib239","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/pbc.25789","article-title":"Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in Down syndrome: a nationwide prospective study in Japan","volume":"63","author":"Taga","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2026040211214354200_bib240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood.2025030775","article-title":"CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 Trial","volume":"147","author":"Laszig","year":"2026","journal-title":"Blood"},{"issue":"9","key":"2026040211214354200_bib241","doi-asserted-by":"crossref","first-page":"e31141","DOI":"10.1002\/pbc.31141","article-title":"Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndrome","volume":"71","author":"Miladinovic","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"21","key":"2026040211214354200_bib242","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1182\/bloodadvances.2022009381","article-title":"Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome","volume":"7","author":"Raghuram","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2026040211214354200_bib243","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/blood-2007-09-114231","article-title":"Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study","volume":"111","author":"Forestier","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2026040211214354200_bib244","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cyto.b.22118","article-title":"The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease","volume":"104","author":"Hsu","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"issue":"7","key":"2026040211214354200_bib245","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00277-021-04531-x","article-title":"Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis","volume":"100","author":"Gadgeel","year":"2021","journal-title":"Ann Hematol"},{"issue":"4","key":"2026040211214354200_bib246","doi-asserted-by":"crossref","first-page":"e28099","DOI":"10.1002\/pbc.28099","article-title":"Causes of early death and treatment-related death in newly diagnosed pediatric acute myeloid leukemia: recent experiences of the Dutch Childhood Oncology Group","volume":"67","author":"Klein","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2026040211214354200_bib247","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/978-3-031-44080-9_71","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Gibson","year":"2024"},{"issue":"3","key":"2026040211214354200_bib248","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1097\/PTS.0000000000000911","article-title":"Challenges and barriers to adverse event reporting in clinical trials: a Children's Oncology Group Report","volume":"18","author":"Miller","year":"2022","journal-title":"J Patient Saf"},{"issue":"12","key":"2026040211214354200_bib249","doi-asserted-by":"crossref","first-page":"e29986","DOI":"10.1002\/pbc.29986","article-title":"Longitudinal use of patient reported outcomes in pediatric leukemia and lymphoma reveals clinically relevant symptomatic adverse events","volume":"69","author":"Jacobs","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2026040211214354200_bib250","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026040211214354200_bib251","first-page":"374","article-title":"Challenges of clinical trial design for targeted agents against pediatric leukemias","volume":"4","author":"Mussai","year":"2014","journal-title":"Front Oncol"},{"issue":"10","key":"2026040211214354200_bib252","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2026040211214354200_bib253","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MOP.0000000000000855","article-title":"Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy","volume":"32","author":"Elgarten","year":"2020","journal-title":"Curr Opin Pediatr"},{"issue":"6","key":"2026040211214354200_bib254","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ajh.26142","article-title":"Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia","volume":"96","author":"Fathi","year":"2021","journal-title":"Am J Hematol"},{"issue":"10","key":"2026040211214354200_bib255","doi-asserted-by":"crossref","first-page":"e2128385","DOI":"10.1001\/jamanetworkopen.2021.28385","article-title":"Home or away from home: a multi-institution study comparing medical outcomes, patient perspectives, and health-related quality of life for outpatient versus inpatient management after chemotherapy for pediatric acute myeloid leukemia","volume":"4","author":"Getz","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026040211214354200_bib256","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00314","article-title":"AML care at home: an evidence-based toolkit to personalize the care setting for recovery from pediatric AML chemotherapy","author":"Seif","year":"19  2025","journal-title":"JCO Oncol Pract"},{"issue":"23","key":"2026040211214354200_bib257","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.2016.66.7881","article-title":"Lack of effectiveness of neutropenic diet and social restrictions as anti-infective measures in children with acute myeloid leukemia: an analysis of the AML-BFM 2004 Trial","volume":"34","author":"Tramsen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026040211214354200_bib258","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2007-05-091942","article-title":"Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia","volume":"110","author":"Sung","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2026040211214354200_bib259","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/sj.leu.2403188","article-title":"Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93","volume":"18","author":"Lehrnbecher","year":"2004","journal-title":"Leukemia"},{"issue":"1","key":"2026040211214354200_bib260","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1038\/bcj.2015.110","article-title":"Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004","volume":"6","author":"Bochennek","year":"2016","journal-title":"Blood Cancer J"},{"issue":"10","key":"2026040211214354200_bib261","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2018.12512","article-title":"Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial","volume":"320","author":"Alexander","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"2026040211214354200_bib262","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/cid\/ciz1082","article-title":"Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation","volume":"71","author":"Lehrnbecher","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2026040211214354200_bib263","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(20)30725-7","article-title":"Eighth European Conference on Infections in Leukaemia (ECIL-8): 2020 guidelines for the use of antibiotics in paediatric patients with cancer or haematopoietic cell transplantation","volume":"22","author":"Lehrnbecher","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026040211214354200_bib264","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.cmi.2018.02.031","article-title":"Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays?","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"2026040211214354200_bib265","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijantimicag.2018.04.014","article-title":"Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Tandan","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"18","key":"2026040211214354200_bib266","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.2016.71.7017","article-title":"Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update","volume":"35","author":"Lehrnbecher","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026040211214354200_bib267","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cmi.2024.06.002","article-title":"Infectious complications in the paediatric immunocompromised host: a narrative review","volume":"31","author":"Lehrnbecher","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"2026040211214354200_bib268","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"Eighth European Conference on Infections in Leukaemia (ECIL-8): 2020 updated guidelines for diagnosis, prevention and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"2026040211214354200_bib269","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM198706253162604","article-title":"Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis","volume":"316","author":"Hughes","year":"1987","journal-title":"N Eng J Med"},{"issue":"27","key":"2026040211214354200_bib270","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.20.00158","article-title":"Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients","volume":"38","author":"Lehrnbecher","year":"2020","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026040211214354200_bib271","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jama.2019.15702","article-title":"Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial","volume":"322","author":"Fisher","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"2026040211214354200_bib272","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"2026040211214354200_bib273","doi-asserted-by":"crossref","first-page":"e0212837","DOI":"10.1371\/journal.pone.0212837","article-title":"A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia","volume":"14","author":"Arrieta","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"2026040211214354200_bib274","doi-asserted-by":"crossref","first-page":"106084","DOI":"10.1016\/j.ijantimicag.2020.106084","article-title":"Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial","volume":"56","author":"Groll","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"2026040211214354200_bib275","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"2026040211214354200_bib276","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"2026040211214354200_bib277","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jpids\/piab036","article-title":"Prospective evaluation of galactomannan and (1\u21923) \u03b2-d-glucan assays as diagnostic tools for invasive fungal disease in children, adolescents, and young adults with acute myeloid leukemia receiving fungal prophylaxis","volume":"10","author":"Fisher","year":"2021","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"1","key":"2026040211214354200_bib278","doi-asserted-by":"crossref","first-page":"e14399","DOI":"10.1111\/petr.14399","article-title":"Prospective evaluation of the fungitell(R) (1--&gt;3) beta-D-glucan assay as a diagnostic tool for invasive fungal disease in pediatric allogeneic hematopoietic cell transplantation: a report from the Children's Oncology Group","volume":"27","author":"Otto","year":"2023","journal-title":"Pediatr Transpl"},{"issue":"5","key":"2026040211214354200_bib279","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cvr\/cvz031","article-title":"Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment","volume":"115","author":"Chow","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2026040211214354200_bib280","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/hematology.2022000342","article-title":"Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity","volume":"2022","author":"Bottinor","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"2026040211214354200_bib281","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/pbc.21105","article-title":"Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML","volume":"48","author":"Creutzig","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"suppl 1","key":"2026040211214354200_bib282","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2019-131227","article-title":"Occurrence and resolution of anthracycline cardiotoxicity and impact on treatment outcomes among children treated on the AAML1031 clinical trial: a report from the Children's Oncology Group","volume":"134","author":"Getz","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2026040211214354200_bib283","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jaccao.2025.05.009","article-title":"IGHG recommendations for anthracycline and anthraquinone cardiac dysfunction equivalence ratios after childhood cancer: JACC: CardioOncology Expert Panel","volume":"7","author":"Kouwenberg","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"6","key":"2026040211214354200_bib284","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","article-title":"Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity","volume":"5","author":"Feijen","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026040211214354200_bib285","doi-asserted-by":"crossref","first-page":"1286241","DOI":"10.3389\/fcvm.2023.1286241","article-title":"Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy","volume":"10","author":"Leger","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"2026040211214354200_bib286","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2352-4642(22)00239-5","article-title":"Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"6","author":"de Baat","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"21","key":"2026040211214354200_bib287","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.19.02856","article-title":"Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"38","author":"Getz","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026040211214354200_bib288","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/14737140.2022.2131544","article-title":"Supportive care in pediatric acute myeloid leukemia:expert-based recommendations of the NOPHO-DB-SHIP consortium","volume":"22","author":"Arad-Cohen","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"2026040211214354200_bib289","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2006-07-035915","article-title":"Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia","volume":"109","author":"Lehrnbecher","year":"2007","journal-title":"Blood"},{"issue":"15","key":"2026040211214354200_bib290","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2009.25.9010","article-title":"Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse","volume":"28","author":"Ehlers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026040211214354200_bib291","doi-asserted-by":"crossref","first-page":"e27701","DOI":"10.1002\/pbc.27701","article-title":"Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01","volume":"66","author":"L\u00f8hmann","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"28","key":"2026040211214354200_bib292","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026040211214354200_bib293","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10147-023-02465-0","article-title":"Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology","volume":"29","author":"Maeda","year":"2024","journal-title":"Int J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024027904\/2511702\/blood_bld-2024-027904-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024027904\/2511702\/blood_bld-2024-027904-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:22:20Z","timestamp":1775143340000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/14\/1532\/547835\/Diagnosis-and-management-of-AML-in-pediatric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":293,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027904","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,2]]},"published":{"date-parts":[[2026,4,2]]}}}